[3-(9-chloro-11-fluoro-1,8-dithia-dibenzo[e,h]azulene-2-ylmethoxy)-propyl]-dimethyl-amine Hydrochloride | 374801-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: [3-(9-chloro-11-fluoro-1,8-dithia-dibenzo[e,h]azulene-2-ylmethoxy)-propyl]-dimethyl-amine Hydrochloride
• 英文别名: 3-[(15-chloro-17-fluoro-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]-N,N-dimethylpropan-1-amine;hydrochloride
• CAS: 374801-02-2
• 化学式: C₂₂H₂₁ClFNOS₂*ClH
• 分子量: 470.459
• InChiKey: PXCXNYYBFSAIKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.23
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
  申请人：Pliva farmaceutska industrija, dionicko drustvo

  公开号：US20030153750A1

  公开（公告）日：2003-08-14

  The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-&agr;) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.

  本发明涉及由公式I表示的二苯并蓝化合物，以及它们的制药制剂，用于抑制哺乳动物在所有过度分泌这些介质的疾病和情况中的肿瘤坏死因子α（TNF-α）和白细胞介素1（IL-1）。本发明的化合物还表现出镇痛作用，可用于缓解疼痛。
• Pellet formulation for the treatment of the intestinal tract
  申请人：Dr. Falk Pharma GmbH.

  公开号：US20030133983A1

  公开（公告）日：2003-07-17

  An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

  本发明公开了一种用于治疗肠道的可口服药物颗粒制剂，该制剂由核心和肠衣组成，核心包括作为药物活性化合物的氨基水杨酸或其药用耐受盐或衍生物。
• THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS
  申请人：GlaxoSmithKline istrazivacki centar Zagreb d.o.o.

  公开号：EP1284977B1

  公开（公告）日：2009-06-24
• PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES
  申请人：Amura Therapeutics Limited

  公开号：EP1546150B1

  公开（公告）日：2009-03-04
• PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT
  申请人：Otterbeck Norbert

  公开号：US20090017117A1

  公开（公告）日：2009-01-15

  An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.